AR and posterior cortical atrophy: Currently, therapeutic options for advanced PCa include AR signaling inhibitors (ARIs - abiraterone, enzalutamide, apalutamide), antimicrotubule agents (docetaxel, cabazitaxel), and immune therapy (sipuleucel-T).